Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nicox SA.
  6. News
  7. Press Releases
    COX   FR0013018124

NICOX SA.

(COX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
CommuniquÚs de presse de la sociÚtÚ NICOX SA.
01/06NICOX : Half-year liquidity contract statement for NICOX
AQ
01/05Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030
AQ
2021Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 T..
AQ
2021Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-c..
AQ
2021Nicox Restructures Kreos Capital Bond Financing Agreement and Raises Ç15 Million in Pri..
AQ
2021Number of voting rrights as of November 30, 2021
AQ
2021Nicox's Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path..
AQ
2021Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europe
AQ
2021Nicox's NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the A..
AQ
2021Number of voting rightts as of October 31
AQ
2021NICOX : Provides Third Quarter 2021 Business and Financial Highlights
AQ
2021NICOX : to present at the OIS Glaucoma Virtual Innovation Showcase
AQ
2021NICOX : Launches New Corporate & Investor Website
AQ
2021NICOX : NCX 470 Shows Retinal Cell Protection in a Nonclinical Model
AQ
2021NICOX : First Half 2021 Financial Results and Business Update
AQ
2021NICOX : Announces Results from the NCX 4251 Phase 2b Mississippi Blepharitis Trial
AQ
2021NICOX : Provides Second Quarter 2021 Business and Financial Highlights and Strategic Updat..
GL
2021NICOX : Appoints Robert N. Weinreb, M.D. and Sanjay G. Asrani, M.D. to its Glaucoma Clinic..
AQ
2021NICOX : Half-year liquidity contract statement with Kepler Cheuvreux
GL
2021NICOX : to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment un..
AQ
2021NICOX : Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trial
GL
2021Nicox's NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Pha..
GL
2021NICOX : Licensee Bausch + Lomb Receives Approval for VYZULTA« (latanoprostene bunod ophtha..
AQ
2021NICOX : NCX 470 Dolomites Phase 2 Results in Glaucoma Patients To Be Presented at the Worl..
GL
2021NICOX : Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Tria..
GL
2021NICOX : partners with Laboratorios Grin to bring ZERVIATE to Mexico
GL
2021NICOX : Licensee Bausch + Lomb Launches VYZULTA« (latanoprostene bunod ophthalmic solution..
PU
2021NICOX : Licensee Bausch + Lomb Launches VYZULTA« (latanoprostene bunod ophthalmic solution..
GL
2021NICOX : NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollment
GL
2021U.S. Patents for Nicox's Latanoprostene Bunod, Commercialized as VYZULTA«, Eligible for..
GL
2021BAUSCH HEALTH : Announces VYZULTA (latanoprostene bunod ophthalmic solution), 0.024%, is N..
AQ
2021NICOX : Provides First Quarter 2021 Business Update and Financial Highlights
AQ
2021NICOX : Bausch health announces vyzulta« (latanoprostene bunod ophthalmic solution), 0.024..
GL
2021NICOX : Bausch health announces vyzulta« (latanoprostene bunod ophthalmic solution), 0.024..
AQ
2021NICOX : Broadcast live and record in audio format of the Ordinary general meeting and Extr..
PU
2021NICOX : 2021 Ordinary and Extraordinary General Meetings postponed to April 28, 2021
GL
2021NICOX S A : NCX 470 Mont Blanc Phase 3 Glaucoma Trial Reaches 50% Enrollment Milestone
GL
2021NICOX : 2021 Extraordinary and Ordinary Shareholder Meetings
GL
2021Nicox's NCX 470 Receives Approval by Chinese Authorities for Local Start of Denali Phas..
GL
2021NICOX S A : Provides Video Update on Latest Developments
AQ
2021NICOX S A : Announces 2020 Financial Results and 2021 Key Milestones
AQ
2021NICOX S A : Announces the Publication in Leading Scientific Journal of Pre-Clinical Effica..
AQ
2021NICOX S A : U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE« In Agreement with H..
GL
2021BAUSCH HEALTH : Announces VYZULTA, 0.024%, is Now Approved in South Korea
AQ
2021NICOX S A : Bausch Health Announces Vyzulta« (latanoprostene Bunod Ophthalmic Solution), 0..
AQ
2021Bausch Health Announces Vyzulta« (latanoprostene Bunod Ophthalmic Solution), 0.024%, is..
GL
2021NICOX S A : to Present at the H.C. Wainwright Virtual BioConnect Conference
PU
2021Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 20..
GL
2021NICOX S A : Analyst Coverage Initiated by Edison Investment Research
GL
2021NICOX S A : Provides Fourth Quarter 2020 Business Update and Financial Highlights
AQ
2021NICOX S A : Provides Fourth Quarter 2020 Business Update and Financial Highlights
GL
2021NICOX : Half-year liquidity contract statement with Kepler Cheuvreux
GL
2021NICOX S A : Licensee Bausch + Lomb Launches VYZULTA in Mexico
GL
2021NICOX S A : Licensee Bausch + Lomb Launches VYZULTA in Mexico
AQ
2021Nicox Highlights Successful 2020 Development Progress and Clinical Milestones for 2021
GL
2021NICOX S A : Highlights Successful 2020 Development Progress and Clinical Milestones for 20..
AQ
2020NICOX S A : Partner Ocumension Therapeutics Initiates ZERVIATE Phase 3 Clinical Trial in C..
GL
2020NICOX S A : Licensee Bausch + Lomb Secures Approval of VYZULTA« in Colombia
PU
2020Nicox's Licensee Bausch + Lomb Secures Approval of VYZULTA in Colombia
GL
2020NICOX S A : Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for..
AQ
2020NICOX S A : Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential Covid-19 ..
GL
2020NICOX S A : Raises Ç15 million in Private Placement
GL
2020NICOX S A : Analyst Coverage Initiated by Kepler Cheuvreux
AQ
2020NICOX S A : Analyst Coverage Initiated by Kepler Cheuvreux
AQ
2020NICOX S A : Analyst Coverage Initiated by Kepler Cheuvreux
GL
2020NICOX S A : Licensee Bausch + Lomb Launches VYZULTA« in Argentina
PU
2020NICOX S A : Licensee Bausch + Lomb Launches VYZULTA in Argentina
AQ
2020NICOX S A : Licensee Bausch + Lomb Launches VYZULTA in Argentina
GL
2020NICOX S A : Licensee Bausch + Lomb Launches VYZULTA in Argentina
AQ
2020Nicox's Licensee Bausch + Lomb Launches VYZULTA in Argentina
GL
2020NICOX S A : Initiates Second Phase 3 Trial of NCX 470 in Glaucoma
PU
2020NICOX S A : Initiates Second Phase 3 Trial of NCX 470 in Glaucoma
AQ
2020NICOX S A : Initiates Second Phase 3 Trial of NCX 470 in Glaucoma
GL
2020NICOX S A : Initiates Second Phase 3 Trial of NCX 470 in Glaucoma
AQ
2020Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucoma
GL
1  2  3  4  5Next
Upcoming event on NICOX SA.
03/10/22